SYDNEXIS
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.
SYDNEXIS
Industry:
Manufacturing Pharmaceutical
Founded:
2014-01-01
Address:
Del Mar, California, United States
Country:
United States
Website Url:
http://www.sydnexis.com
Total Employee:
11+
Status:
Active
Contact:
(619) 507-9827
Email Addresses:
[email protected]
Total Funding:
50.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Longitude Capital
Longitude Capital investment in Series B - Sydnexis
Medicxi
Medicxi investment in Series B - Sydnexis
Bluestem Capital
Bluestem Capital investment in Series B - Sydnexis
Visionary Venture Fund
Visionary Venture Fund investment in Series B - Sydnexis
RA Capital Management
RA Capital Management investment in Series B - Sydnexis
SC Master Fund
SC Master Fund investment in Series B - Sydnexis
Medicxi
Medicxi investment in Venture Round - Sydnexis
RA Capital Management
RA Capital Management investment in Venture Round - Sydnexis
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-16 | Perry J. Sternberg Joins Sydnexis as Chief Executive Officer |
| 2023-08-29 | Sydnexis Welcomes Nick Ruth as Chief Commercial Officer |
Official Site Inspections
http://www.sydnexis.com Semrush global rank: 11.44 M Semrush visits lastest month: 162
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Sydnexis"
About Sydnexis
Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD …See details»
Sydnexis - Crunchbase Company Profile & Funding
Organization. Sydnexis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Sydnexis is engaged in the development of a …See details»
Management at Sydnexis
Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, …See details»
Sydnexis Company Profile | Management and Employees List
Sydnexis Profile and History. Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a …See details»
Sydnexis Company Profile 2024: Valuation, Funding
Sydnexis General Information Description. Developer of a eyecare medicine and drug designed to treat myopia. The company offers a topical eyedrop formulation used to treat the progression of myopia in children, enabling medical …See details»
Sydnexis, Inc. Company Profile | Del Mar, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Sydnexis, Inc. of Del Mar, CA. Get the latest business insights from Dun & Bradstreet.See details»
Sydnexis - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Aug 10, 2021: Series B - …See details»
Sydnexis Stories, Data, Wiki and Company News | HackerNoon
Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD …See details»
Sydnexis - Overview, News & Similar companies | ZoomInfo.com
Aug 9, 2021 Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital SAN DIEGO--(BUSINESS WIRE)--Sydnexis, Inc., a clinical stage …See details»
Sydnexis Company Profile - Office Locations, Competitors ... - Craft
Sydnexis is a clinical-stage biopharmaceutical company developing a proprietary formulation for decreasing myopic progression in children. It offers SYD-101, an eyedrop formulation.See details»
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer
DEL MAR, Calif., July 16, 2024--Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is …See details»
Sydnexis - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Sydnexis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Sydnexis has 5 current employee profiles, …See details»
Sydnexis - Org Chart, Teams, Culture & Jobs - The Org
View Sydnexis' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Sydnexis, Inc. | TREA
OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF. Publication number 20230381016; Publication date Nov 30, 2023; Sydnexis, Inc. Gregory I. OstrowSee details»
Sydnexis Management - Perry J. Sternberg
Perry brings to Sydnexis over 30 years of commercial leadership including oversight of more than 20 product launches across a wide range of therapeutic areas and markets. His tenure in eye …See details»
Sydnexis Names Perry J. Sternberg CEO - Review of Myopia …
July 16, 2024 DEL MAR, Calif. — Sydnexis has officially named a new Chief Executive Officer and member of the Board of Directors, Perry J. Sternberg. An accomplished pharma/biotech …See details»
Sydnexis CEO and Key Executive Team | Craft.co
Sydnexis's Chief Executive Officer and Director is Ken Widder. Other executives include Jacki Johnson, Chief Operating Officer; Patrick Johnson, Chief Business Officer. See the full …See details»
Sydnexis welcomes Perry J. Sternberg as Chief Executive Officer
DEL MAR, CA - July 16, 2024 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is …See details»
Why Myopia? - Sydnexis
Founded in 2014, Sydnexis Inc. is a privately held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently evaluating its patented eyedrop formulation, SYD …See details»